At the core of this cycle are T cells, the immune system's primary cancer-fighting cells. But T cells do not work alone; they rely on activation from other immune cells, particularly antigen ...

Its design mirrors the previous Phase III FLASH study, which consisted of three six-week treatment cycles, with the assessment of primary efficacy at the end of the first six-week cycle.